Drugs / Amniotic and Umbilical Cord Tissue Procedure
Amniotic and Umbilical Cord Tissue Procedure
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03899298 | Sep 2019 → Mar 2024 overdue | Alzheimer disease, arthritic joint disease, autoimmune disease, cardiomyopathy +7 | R3 Stem Cell | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amniotic and Umbilical Cord Tissue Procedure | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03899298 ↗ |
| Modality | Cell therapy | “Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.” NCT03899298 ↗ |
| Route | Intranasal | “Depending on the condition, patients may receive a series of therapies via one or more of the following methods: intravenous, injection, intra-nasal and/or nebulizer.” NCT03899298 ↗ |
| Route | Intravenous | “Depending on the condition, patients may receive a series of therapies via one or more of the following methods: intravenous, injection, intra-nasal and/or nebulizer.” NCT03899298 ↗ |